title: Management of alcoholic liver disease: an update.
abstract: Treatment of alcoholic liver disease is for the most part based on the stage of the disease and the pathogenic event that is being targeted. The primary treatment modalities that are considered in the treatment of alcoholic liver disease include abstinence, agents that suppress inflammation, anticytokine therapy, nutritional support, modifiers of alcohol metabolism, anti-oxidants, and inhibitors of hepatic fibrosis. Future therapeutic options include exploration of new pathways such as the patatin-like phospholipase domain containing 3 protein (PNPLA-3).
authors.affiliation: Department of Experimental Medicine, Faculty of Medicine, UNAM, Hospital General de Mexico, Mexico DF, Mexico. kesdhipa@yahoo.com
authors.forename: David
authors.initials: D
authors.lastname: Kershenobich
authors.forename: Dana Lau
authors.initials: DL
authors.lastname: Corona
authors.forename: Ruben
authors.initials: R
authors.lastname: Kershenovich
authors.forename: Gabriela
authors.initials: G
authors.lastname: Gutierrez-Reyes
mesh_terms: D000437:Alcoholism / Q000235:genetics / Q000473:pathology / Q000628:therapy; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D019468:Disease Management; D015316:Genetic Therapy / Q000639:trends; D006801:Humans; D008049:Lipase / Q000235:genetics; D008108:Liver Diseases, Alcoholic / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D008565:Membrane Proteins / Q000235:genetics; D018529:Nutritional Support / Q000379:methods; D013695:Temperance; D000217:Acyltransferases; D054512:Phospholipases A2, Calcium-Independent
chemical_list: D000893:Anti-Inflammatory Agents; D008049:Lipase; D008565:Membrane Proteins; C533682:PNPLA3 protein, human; D000217:Acyltransferases; D054512:Phospholipases A2, Calcium-Independent